Skip to main content

Advertisement

SpringerLink
Log in

Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide

  • Clinical Study – Patient Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Targeting angiogenesis in glioblastoma (GBM) may improve patient outcome by normalizing tumor vasculature and improving delivery of chemotherapeutics and oxygen. Consequently, concomitant administration of small molecule inhibitors of the VEGF pathway will likely have a positive impact on chemoradiation treatment outcome. We conducted a Phase I study of vatalanib, a small molecule inhibitor of VEGFR, PDGFR, and c-kit in patients with newly diagnosed GBM receiving radiation, temozolomide, and an enzyme-inducing anti-epileptic drug in order to determine the MTD of vatalanib in this patient population. We incorporated circulating biomarker and SNP analyses and pharmacokinetic studies. Nineteen patients were enrolled and the MTD was not reached at the time of study termination. Vatalanib was well tolerated with only 2 DLTs (thrombocytopenia and elevated transaminases). Other grade 3/4 toxicities included leukopenia, lymphopenia, neutropenia, and hand-foot syndrome. There were no wound-healing complications. Of the 13 patients evaluable for a radiographic response, 2 had a partial response and 9 had stable disease. Vatalanib significantly increased PlGF and sVEGFR1 in plasma circulation and decreased sVEGFR2 and sTie2. Plasma collagen IV increased significantly by day 50 of treatment. Vatalanib was well tolerated and this study demonstrates the safety of oral small molecule inhibitors in newly diagnosed GBM patients. Blood biomarkers may be useful as pharmacodynamic markers of response to anti-angiogenic therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Jain R (2005) Antiangiogenic therapy for cancer: current and emerging concepts. Oncology 19(4 Suppl 3):7–16

    PubMed  Google Scholar 

  2. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, di Tomaso E, Munn LL, Jain RK, Winkler F, Kozin SV, Tong RT, Chae S-S, Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, di Tomaso E, Munn LL, Jain RK (2004) Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6(6):553–563

    PubMed  CAS  Google Scholar 

  3. Jain R (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58–62

    Article  PubMed  CAS  Google Scholar 

  4. Wood J, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O’Reilly T, Persohn E, Rosel J, Schnell C, Stover D, Theuer A, Towbin H, Wenger F, Woods-Cook K, Menrad A, Siemeister G, Schirner M, Thierauch K, Schneider M, Drevs J, Martiny-Baron G, Totzke F (2000) PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60(8):2178–2189

    PubMed  CAS  Google Scholar 

  5. Thomas AL, Morgan B, Horsfield MA, Higginson A, Kay A, Lee L, Masson E, Puccio-Pick M, Laurent D, Steward WP (2005) Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol 23(18):4162–4171

    Article  PubMed  CAS  Google Scholar 

  6. Goldbrunner R, Bendszus M, Wood J, Kiderlen M, Sasaki M, Tonn J (2004) PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization. Neurosurgery 55(2):426–432

    Article  PubMed  Google Scholar 

  7. Conrad C, Friedman H, Reardon D, Provenzale J, Jackson E, Serajuddin H, Laurent D, Chen B, Yung WKA (2004) A phase I/II trial of single-agent PTK 787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM). ASCO Annual Meeting Proceedings: Abstr 1512

  8. Reardon D, Friedman H, Yung WKA, Brada M, Conrad C, Provenzale J, Jackson E, Serajuddin H, Chen B, Laurent D (2004) A phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM). ASCO Annual Meeting Proceedings: Abstr 1513

  9. Reardon DA, Egorin MJ, Desjardins A, Vredenburgh JJ, Beumer JH, Lagattuta TF, Gururangan S, Herndon JE II, Salvado AJ, Friedman HS (2009) Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. Cancer 115(10):2188–2198. doi:10.1002/cncr.24213

    Article  PubMed  CAS  Google Scholar 

  10. Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KD (2008) Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26(11):1810–1816. doi:JCO.2007.14.5375[pii]10.1200/JCO.2007.14.5375

    Article  PubMed  CAS  Google Scholar 

  11. Drevs J MM, Mross K et al (2005) Phase I clinical evaluation of AZD2171, a highly potent VEGF receptor tyrosine kinase inhibitor, in patients with advanced tumors. J Clin Oncol 23:Abstract 3002

  12. Drevs J, Zirrgiebel U, Schmidt-Gersbach CI, Mross K, Medinger M, Lee L, Pinheiro J, Wood J, Thomas AL, Unger C, Henry A, Steward WP, Laurent D, Lebwohl D, Dugan M, Marme D (2005) Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. Ann Oncol 16(4):558–565. doi:mdi118[pii]10.1093/annonc/mdi118

    Article  PubMed  CAS  Google Scholar 

  13. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24(1):16–24. doi:JCO.2005.02.2574[pii]10.1200/JCO.2005.02.2574

    Article  PubMed  CAS  Google Scholar 

  14. Norden-Zfoni A, Desai J, Manola J, Beaudry P, Force J, Maki R, Folkman J, Bello C, Baum C, DePrimo SE, Shalinsky DR, Demetri GD, Heymach JV (2007) Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res 13(9):2643–2650. doi:13/9/2643[pii]10.1158/1078-0432.CCR-06-0919

    Article  PubMed  CAS  Google Scholar 

  15. Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhwani V, Blaszkowsky LS, Yoon SS, Lahdenranta J, Bhargava P, Meyerhardt J, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger PC, Fuchs CS, Ryan DP, Jain RK (2009) Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 27(18):3027–3035. doi:JCO.2008.20.9908[pii]10.1200/JCO.2008.20.9908

    Article  PubMed  CAS  Google Scholar 

  16. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8(7):1277–1280

    PubMed  CAS  Google Scholar 

  17. Duda DG, Cohen KS, Scadden DT, Jain RK, Duda DG, Cohen KS, Scadden DT, Jain RK (2007) A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood. Nat Protoc 2(4):805–810

    Article  PubMed  CAS  Google Scholar 

  18. Sorensen AG, Batchelor TT, Zhang WT, Chen PJ, Yeo P, Wang M, Jennings D, Wen PY, Lahdenranta J, Ancukiewicz M, di Tomaso E, Duda DG, Jain RK (2009) A “Vascular normalization index” As potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res 69(13):5296–5300. doi:0008-5472.CAN-09-0814[pii]10.1158/0008-5472.CAN-09-0814

    Article  PubMed  CAS  Google Scholar 

  19. Brandes AA, Stupp R, Hau P, Lacombe D, Gorlia T, Tosoni A, Mirimanoff RO, Kros JM, van den Bent MJ (2009) Eortc study 26041–22041: Phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma. Eur J Cancer 46(2):348–354. doi:S0959-8049(09)00816-8[pii]10.1016/j.ejca.2009.10.029

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Stephen E. & Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit Street, Yawkey 9E, Boston, MA, 02114, USA

    Elizabeth R. Gerstner, April F. Eichler, Scott R. Plotkin, Colin L. Doyle & Tracy T. Batchelor

  2. Department of Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

    Jan Drappatz & Patrick Y. Wen

  3. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA

    Lei Xu, Dan G. Duda & Rakesh K. Jain

Authors
  1. Elizabeth R. Gerstner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. April F. Eichler
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Scott R. Plotkin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jan Drappatz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Colin L. Doyle
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lei Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Dan G. Duda
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Patrick Y. Wen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Rakesh K. Jain
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Tracy T. Batchelor
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elizabeth R. Gerstner.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOC 148 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gerstner, E.R., Eichler, A.F., Plotkin, S.R. et al. Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide. J Neurooncol 103, 325–332 (2011). https://doi.org/10.1007/s11060-010-0390-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-010-0390-7

Keywords

Search

Navigation